Overview

• Phase 3 VIITAL trial showed 81% of chronic EB wounds treated with Zevaskyn achieved at least 50% closure by week 24 versus 16% with standard care
• Zevaskyn recipients experienced nearly three times the pain relief reported by control participants over the same period
• The therapy works by modifying patients’ own skin cells to deliver a functional COL7A1 gene and correct the genetic defect in recessive dystrophic EB
• Stanford researchers highlight the potential of this gene-corrected skin graft platform for other genetic diseases and aim to study its effects in younger patients
• Availability is expected to be limited to select centers and may hinge on insurance approval, raising concerns over equitable access